<tr id='0p3kx'><strong id='0p3kx'></strong><small id='0p3kx'></small><button id='0p3kx'></button><li id='0p3kx'><noscript id='0p3kx'><big id='0p3kx'></big><dt id='0p3kx'></dt></noscript></li></tr><ol id='0p3kx'><option id='0p3kx'><table id='0p3kx'><blockquote id='0p3kx'><tbody id='0p3kx'></tbody></blockquote></table></option></ol><u id='0p3kx'></u><kbd id='0p3kx'><kbd id='0p3kx'></kbd></kbd>
AviadoBio Ltd和安斯泰(tai)來(lai)Astellas Pharma Inc宣布了AVB-101的獨家選項和許可協議，AVB-101是一種基(ji)于aav的研究性基(ji)因療法，處于1/2期開發，用(yong)于治療伴有(you)蛋白前突變(FTD-GRN)的額顳(nie)葉癡(chi)呆患者。(美通社)
<small id='pxv00'></small><noframes id='pKN92'>
<tbody id='zfIJZ'></tbody>
<bdo id='NFPTb'></bdo><ul id='Kehuz'></ul>
